Sodium-glucose cotransporter 2 (SGLT2) inhibitors not only showed glucose-lowering effects but also showed unexpected cardioprotective and renoprotective effects in patients with type 2 diabetes mellitus in large clinical trials [1–6]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.